Gurm Hitinder S, Yadav Jay S, Fayad Pierre, Katzen Barry T, Mishkel Gregory J, Bajwa Tanvir K, Ansel Gary, Strickman Neil E, Wang Hong, Cohen Sidney A, Massaro Joseph M, Cutlip Donald E
University of Michigan School of Medicine, Ann Arbor, USA.
N Engl J Med. 2008 Apr 10;358(15):1572-9. doi: 10.1056/NEJMoa0708028.
We previously reported that, in a randomized trial, carotid stenting with the use of an emboli-protection device is not inferior to carotid endarterectomy for the treatment of carotid artery disease at 30 days and at 1 year. We now report the 3-year results.
The trial evaluated carotid artery stenting with the use of an emboli-protection device as compared with endarterectomy in 334 patients at increased risk for complications from endarterectomy who had either a symptomatic carotid artery stenosis of at least 50% of the luminal diameter or an asymptomatic stenosis of at least 80%. The prespecified major secondary end point at 3 years was a composite of death, stroke, or myocardial infarction within 30 days after the procedure or death or ipsilateral stroke between 31 days and 1080 days (3 years).
At 3 years, data were available for 260 patients (77.8%), including 85.6% of patients in the stenting group and 70.1% of those in the endarterectomy group. The prespecified major secondary end point occurred in 41 patients in the stenting group (cumulative incidence, 24.6%; Kaplan-Meier estimate, 26.2%) and 45 patients in the endarterectomy group (cumulative incidence, 26.9%; Kaplan-Meier estimate, 30.3%) (absolute difference in cumulative incidence for the stenting group, -2.3%; 95% confidence interval, -11.8 to 7.0). There were 15 strokes in each of the two groups, of which 11 in the stenting group and 9 in the endarterectomy group were ipsilateral.
In our trial of patients with severe carotid artery stenosis and increased surgical risk, no significant difference could be shown in long-term outcomes between patients who underwent carotid artery stenting with an emboli-protection device and those who underwent endarterectomy. (ClinicalTrials.gov number, NCT00231270 [ClinicalTrials.gov].).
我们之前报道过,在一项随机试验中,使用栓子保护装置的颈动脉支架置入术在30天和1年时治疗颈动脉疾病并不逊于颈动脉内膜切除术。我们现在报告3年的结果。
该试验评估了在334例因内膜切除术并发症风险增加而患有症状性颈动脉狭窄至少达管腔直径50%或无症状狭窄至少达80%的患者中,使用栓子保护装置的颈动脉支架置入术与内膜切除术的效果。预先设定的3年主要次要终点是术后30天内死亡、中风或心肌梗死,或31天至1080天(3年)内死亡或同侧中风的复合情况。
3年时,有260例患者(77.8%)有可用数据,其中支架置入组患者占85.6%,内膜切除术组患者占70.1%。预先设定的主要次要终点在支架置入组的41例患者中出现(累积发生率,24.6%;Kaplan-Meier估计值,26.2%),在内膜切除术组的45例患者中出现(累积发生率,26.9%;Kaplan-Meier估计值,30.3%)(支架置入组累积发生率的绝对差异为-2.3%;95%置信区间,-11.8至7.0)。两组各有15例中风,其中支架置入组11例为同侧中风,内膜切除术组9例为同侧中风。
在我们对严重颈动脉狭窄且手术风险增加患者的试验中,使用栓子保护装置进行颈动脉支架置入术的患者与接受内膜切除术的患者在长期结局上未显示出显著差异。(ClinicalTrials.gov编号,NCT00231270 [ClinicalTrials.gov]。)